Analyst Conference Summaries

Biotechnology Investor Aids

GlycoMimetics
GLYC

conference date: August 5, 2021 @ 5:30 AM Pacific Time

GlycoMimetics' Possible Rivipansel Revival [October 13, 2020 at Seeking Alpha]

GlycoMimetics' Focus Is On AML Therapy [April 17, 2020 at Seeking Alpha]

GlycoMimetics: Still Potential In AML Therapy [September 5, 2019 at Seeking Alpha]

GlycoMimetics Drug Rivipansel Fails Phase 3 Trial [August 2, 2019]

Analyst Call Notes by William P. Meyers
2021
GlycoMimetics
Q1 2021
GlycoMimetics
Q2 2021
   
May 3, 2021
Aug. 5, 20201
 
 
2020
GlycoMimetics
Q1 2020
GlycoMimetics
Q2 2020
GlycoMimetics
Q3 2020
GlycoMimetics
Q4 2020
May 1, 2020
July 31, 2020
Nov. 6, 2020
March 2, 2021
2019
GlycoMimetics
Q1 2019
GlycoMimetics
Q2 2019
GlycoMimetics
Q3 2019
GlycoMimetics
Q4 2019
May 2, 2019
August 1, 2019
Nov. 7, 2019
Feb. 28, 2020
2018
GlycoMimetics
Q4 2018
May 3, 2018
August 10, 2018
Nov. 2, 2018
March 6, 2019
2017
May 18, 2017
 
 Nov. 8, 2017
March 6, 2018
2016
05/04/2016
08/04/2016
11/04/2016
 03/01/2017
2015
tba
8/6/2015
11/12/2015 
2/29/2016

Biotech Bargain Basement: GlycoMimetics [January 8, 2019]

GlycoMimetics: Buy This Dip [April 4, 2018]

GlycoMimetics Remains Undervalued After Leukemia Data Release [June 14, 2017 at Seeking Alpha]

GlycoMimetics: Undercovered with Catalysts Coming [June 9, 2016 at Seeking Alpha]

GlycoMimetics GMI-1271 Effective in Phase I Leukemia Trial [May 19, 2016]
GlycoMimetics Novel Therapeutic Approach [February 5, 2016 at Seeking Alpha]
I Buy GlycoMimetics [April 6, 2015 at Dissecting the Bull]
GlycoMimetics and Pfizer Initiate Phase 3 Rivipansel Trial [June 23, 2015]
FDA Grants Orphan Drug Status to GMI-1271 [May 14, 2015]

GlycoMimetics (GLYC) is a clinical-stage developer of glycoprotein based therapies, including rivipansel and uproleselan.

GlycoMimetics web site


 

Search

More Analyst Conference Notes:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CLDX
 CLSN
 DRNA
 EPZM
 GILD
 ILMN
 INO
 IONS
 INCY
 ISRG
 MCHP
 MRNA
 PLX
 REGN
 RNA
 SAGE
 SGEN
 SYRS
 TTPH
 VBLT
 VSTM
 XLRN

       

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2021 William P. Meyers